Xinnate https://validator.w3.org/feed/docs/rss2.html EB 2026: 20-22 Jan 2026 1. Home NLS Days: 13-14 Oct 2025 ESDR MEETING: 10-13 Sep 2025 4a. Publications Xinnate Completes Oversubscribed Share Issue of SEK 38,5m Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25 Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-25 Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25 All News All Events All Press Releases 4. Science EB Awareness week: 25-31 Oct 2025 3. Impact 6. News and Events Approved clinical trial application for BioC gel on complex wounds 2. Solution Excellent results from phase I study shows that the BioC gel is safe and well tolerated. Funding secured for the next step of BioC clinical plan Xinnate receives Orphan Drug Designation from US FDA for TCP-25 Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa Xinnate presents TCP-25 data at international dermatology congress Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel. Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm Xinnate completes Phase 1a/b study with TCP-25 Approved clinical trial application for First in Human study on BioC gel 7. Contact Xinnate announces successful FDA meeting for TCP-25 New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa Xinnate appoints Anna-Karin Lindqvist as new COO Xinnate is awarded a prestigious grant from the US Department of Defense New publication: BioC-coated dressing shows promising effect on both infection and inflammation Funding secured for the first clinical study of BioC wound gel 5. About Xinnate has received a prestigious Swedish Research Council grant Great interest for the STM article and coverage in Nature Reviews Drug Discovery Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen. Xinnate is looking for a Chief Operating Officer Breakthrough results published in Science Translational Medicine A new article about BioC results from Lund University Xinnate raises SEK 31 million in oversubscribed share issue